199 related articles for article (PubMed ID: 32467179)
1. NIIMBL-Facilitated Active Listening Meeting between Industry and FDA Identifies Common Challenges for Adoption of New Biopharmaceutical Manufacturing Technologies.
Mantle JL; Lee KH
PDA J Pharm Sci Technol; 2020; 74(5):497-508. PubMed ID: 32467179
[TBL] [Abstract][Full Text] [Related]
2. Summary from Advanced Manufacturing Technology Workshop Held at 6th Accelerating Biopharmaceutical Development Meeting.
Lee KH; Mantle JL
PDA J Pharm Sci Technol; 2021; 75(1):48-63. PubMed ID: 32540863
[TBL] [Abstract][Full Text] [Related]
3. Biomanufacturing readiness levels [BRL]-A shared vocabulary for biopharmaceutical technology development and commercialization.
Kedia SB; Baker JC; Carbonell RG; Lee KH; Roberts CJ; Erickson J; Schiel JE; Rogers K; Schaefer G; Pluschkell S
Biotechnol Bioeng; 2022 Dec; 119(12):3526-3536. PubMed ID: 36071569
[TBL] [Abstract][Full Text] [Related]
4. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD
J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650
[TBL] [Abstract][Full Text] [Related]
5. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
[TBL] [Abstract][Full Text] [Related]
6. Achieving continuous manufacturing: technologies and approaches for synthesis, workup, and isolation of drug substance. May 20-21, 2014 Continuous Manufacturing Symposium.
Baxendale IR; Braatz RD; Hodnett BK; Jensen KF; Johnson MD; Sharratt P; Sherlock JP; Florence AJ
J Pharm Sci; 2015 Mar; 104(3):781-91. PubMed ID: 25470351
[TBL] [Abstract][Full Text] [Related]
7. Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D.
Farid SS; Baron M; Stamatis C; Nie W; Coffman J
MAbs; 2020; 12(1):1754999. PubMed ID: 32449439
[TBL] [Abstract][Full Text] [Related]
8. Driving adoption of new technologies in biopharmaceutical manufacturing.
Schaefer G; Balchunas J; Charlebois T; Erickson J; Hart R; Kedia SB; Lee KH
Biotechnol Bioeng; 2023 Sep; 120(9):2765-2770. PubMed ID: 37053004
[TBL] [Abstract][Full Text] [Related]
9. Managing integrated continuous bioprocesses in real time: Deviations in product quality.
Grampp G; Bosley A; Qadan M; Schiel J; Spasoff A; Valax P; Schaefer G
Biotechnol Prog; 2024; 40(2):e3414. PubMed ID: 38013652
[TBL] [Abstract][Full Text] [Related]
10. Recombinant drug development, regulation, and commercialization: an Indian industry perspective.
Sahoo N; Manchikanti P
BioDrugs; 2011 Apr; 25(2):105-13. PubMed ID: 21230010
[TBL] [Abstract][Full Text] [Related]
11. Achieving continuous manufacturing for final dosage formation: challenges and how to meet them. May 20-21, 2014 Continuous Manufacturing Symposium.
Byrn S; Futran M; Thomas H; Jayjock E; Maron N; Meyer RF; Myerson AS; Thien MP; Trout BL
J Pharm Sci; 2015 Mar; 104(3):792-802. PubMed ID: 25501530
[TBL] [Abstract][Full Text] [Related]
12. Emerging technology: A key enabler for modernizing pharmaceutical manufacturing and advancing product quality.
O'Connor TF; Yu LX; Lee SL
Int J Pharm; 2016 Jul; 509(1-2):492-498. PubMed ID: 27260134
[TBL] [Abstract][Full Text] [Related]
13. Comparability Considerations and Challenges for Expedited Development Programs for Biological Products.
Schrieber SJ; Putnam WS; Chow ECY; Cieslak J; Zhuang Y; Martin SW; Hanson P; Maggio F; Rosado LAR
Drugs R D; 2020 Dec; 20(4):301-306. PubMed ID: 32914381
[TBL] [Abstract][Full Text] [Related]
14. European Medicines Agency workshop on biosimilar monoclonal antibodies: July 2, 2009, London, UK.
Reichert JM; Beck A; Iyer H
MAbs; 2009; 1(5):394-416. PubMed ID: 20065643
[TBL] [Abstract][Full Text] [Related]
15. ISPOR, the FDA, and the Evolving Regulatory Science of Medical Device Products.
O'Neill T; Miksad R; Miller D; Maloney L; John A; Hiller C; Hornberger J
Value Health; 2019 Jul; 22(7):754-761. PubMed ID: 31277820
[TBL] [Abstract][Full Text] [Related]
16. The impact of external innovation on new drug approvals: A retrospective analysis.
Liu X; Thomas CE; Felder CC
Int J Pharm; 2019 May; 563():273-281. PubMed ID: 30664998
[TBL] [Abstract][Full Text] [Related]
17. 'Biosimilar' drugs poised to penetrate market.
Ledford H
Nature; 2010 Nov; 468(7320):18-9. PubMed ID: 21048737
[No Abstract] [Full Text] [Related]
18. Biopharmaceutical benchmarks 2018.
Walsh G
Nat Biotechnol; 2018 Dec; 36(12):1136-1145. PubMed ID: 30520869
[No Abstract] [Full Text] [Related]
19. The Relative Contributions of NIH and Private Sector Funding to the Approval of New Biopharmaceuticals.
Schulthess D; Bowen HP; Popovian R; Gassull D; Zhang A; Hammang J
Ther Innov Regul Sci; 2023 Jan; 57(1):160-169. PubMed ID: 36057746
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
